.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

FDA Approvals

EP. 1: FDA Approval for Lutathera in Neuroendocrine Tumors

January 26th 2018

EP. 2: FDA Approval of Second Dosing Schedule of Nivolumab

January 26th 2018

EP. 3: FDA Approval of Frontline Nivolumab/Ipilimumab Combo in RCC

January 26th 2018

EP. 4: FDA Approval of Durvalumab for Stage III Unresectable NSCLC

January 26th 2018

EP. 5: FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin Lymphoma

January 26th 2018

EP. 6: FDA Approval of Frontline Osimertinib in Frontline EGFR-Mutant NSCLC

January 26th 2018

EP. 7: FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ Melanoma

January 26th 2018

EP. 8: FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

January 26th 2018